{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:12:58Z","timestamp":1760242378788,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T00:00:00Z","timestamp":1497312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN2722001000021"],"award-info":[{"award-number":["HHSN2722001000021"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Adenovirus infections of immunocompromised patients can cause a severe multi-organ disease that often results in the patients\u2019 death. Presently, there are no drugs specifically approved to treat adenovirus infections, and clinicians resort to the off-label use of antivirals that are approved to treat other DNA virus infections, most frequently cidofovir (CDV). CDV, however, has considerable nephrotoxicity, thus it is recommended only for the most severe cases of adenovirus infections. To facilitate the development of effective, non-toxic antivirals against adenovirus, we have developed a permissive animal model based on the Syrian hamster that can be used to test the efficacy of antiviral compounds. Here, we show that in the hamster model, HAdV-C6 is a more useful challenge virus than the previously described HAdV-C5, because it is filtered out by tissue macrophages to a lesser extent. HAdV-C6 has a 10-fold lower LD50 in hamsters than HAdV-C5 and the pathology is caused by virus replication to a larger extent. We show that valganciclovir (VGCV), a drug that was shown to be active against intravenous HAdV-C5 infection previously, is efficacious against HAdV-C6 when administered either prophylactically or therapeutically. Further, we show for the first time that VGCV, and to a lesser extent CDV, can be used to treat respiratory adenovirus infections in the hamster model. These results extend the utility of the hamster model, and demonstrate the efficacy of two drugs available for clinicians to treat adenovirus infections.<\/jats:p>","DOI":"10.3390\/v9060147","type":"journal-article","created":{"date-parts":[[2017,6,14]],"date-time":"2017-06-14T03:19:32Z","timestamp":1497410372000},"page":"147","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["HAdV-C6 Is a More Relevant Challenge Virus than HAdV-C5 for Testing Antiviral Drugs with the Immunosuppressed Syrian Hamster Model"],"prefix":"10.3390","volume":"9","author":[{"given":"Karoly","family":"Toth","sequence":"first","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Saint Louis University, St. Louis, MO 63104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Spencer","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Saint Louis University, St. Louis, MO 63104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoling","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Saint Louis University, St. Louis, MO 63104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Tollefson","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Saint Louis University, St. Louis, MO 63104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wold","sequence":"additional","affiliation":[{"name":"Department of Molecular Microbiology and Immunology, Saint Louis University, St. Louis, MO 63104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,6,13]]},"reference":[{"key":"ref_1","unstructured":"Knipe, D.M., and Howley, P.M. (2013). Adenoviridae. Fields Virology, Lippincott Williams & Wilkins."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.003087-0","article-title":"Adenoviruses: Update on structure and function","volume":"90","author":"Russell","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_3","unstructured":"Knipe, D.M., and Howley, P.M. (2013). Adenoviruses. Fields Virology, Lippincott Williams & Wilkins."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1702555","article-title":"Donor leukocyte infusions in acute lymphocytic leukemia","volume":"26","author":"Collins","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ison, M.G., and Hayden, R.T. (2016). Adenovirus. Microbiol. Spectr., 4.","DOI":"10.1128\/microbiolspec.DMIH2-0020-2015"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1055\/s-0036-1584923","article-title":"Adenovirus: Epidemiology, global spread of novel serotypes, and advances in treatment and prevention","volume":"37","author":"Lynch","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1086\/505498","article-title":"Adenovirus infections in transplant recipients","volume":"43","author":"Ison","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1128\/CMR.00052-07","article-title":"Adenoviruses in immunocompromised hosts","volume":"21","author":"Echavarria","year":"2008","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5476","DOI":"10.1182\/blood-2010-04-259291","article-title":"How I treat adenovirus in hematopoietic stem cell transplant recipients","volume":"116","author":"Lindemans","year":"2010","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/rmv.589","article-title":"Clinical features and treatment of adenovirus infections","volume":"18","author":"Lenaerts","year":"2008","journal-title":"Rev. Med. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1586\/14787210.2013.836964","article-title":"Diagnosis and treatment of adenovirus infection in immunocompromised patients","volume":"11","author":"Boztug","year":"2013","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1556\/OH.2012.29496","article-title":"Adenovirus infections in immunocompromised patients","volume":"153","author":"Stercz","year":"2012","journal-title":"Orv. Hetil."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients","volume":"27","author":"Lion","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1053\/j.ajkd.2005.02.010","article-title":"Antiviral drug-induced nephrotoxicity","volume":"45","author":"Izzedine","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.antiviral.2006.04.007","article-title":"Antiviral therapy for adenovirus infections","volume":"71","author":"Lenaerts","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1517\/14656566.2015.1083975","article-title":"New drug on the horizon for treating adenovirus","volume":"16","author":"Wold","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.bbmt.2011.09.007","article-title":"Safety and efficacy of cmx001 as salvage therapy for severe adenovirus infections in immunocompromised patients","volume":"18","author":"Florescu","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_18","unstructured":"Grimley, M., Papanicolaou, G., Maron, G., Chittick, G., Brundage, T., Bae, A., Mommej-Marin, H., Nichols, W., and Prasad, V. (2015, January 22\u201325). In Improved outcomes in allogeneic hematopoietic cell transplant (allo hct) patients treated with brincidofovir for disseminated adenovirus (AdV) disease compared to literature: Updated preliminary results from the advise (cmx001-304) study. Proceedings of the 41st Annual Meeting of the European Society for Blood and Marrow Transplantation, Istanbul, Turkey."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Grimley, M., Maron, G., Prasad, V., Jacobsohn, D., Young, J., Chittick, G., Brundage, T., and Mommeja-Marin, H. (2015, January 11\u201315). In Preliminary results from the advise study evaluating brincidofovir (bcv, cmx001) for the treatment of disseminated and high-risk adenovirus (AdV) infection. Proceedings of the Bone Marrow Transplant Tandem Meetings, San Diego, CA, USA.","DOI":"10.1016\/j.bbmt.2014.11.136"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.bbmt.2016.12.621","article-title":"Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: A randomized placebo-controlled phase ii trial","volume":"23","author":"Grimley","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2016.07.021","article-title":"The use of brincidofovir for the treatment of mixed dsDNA viral infection","volume":"83","author":"Camargo","year":"2016","journal-title":"J. Clin. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/tid.12582","article-title":"Brincidofovir clearance of acyclovir-resistant herpes simplex virus-1 and adenovirus infection after stem cell transplantation","volume":"18","author":"Voigt","year":"2016","journal-title":"Transpl. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-398342-8.00003-3","article-title":"Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds","volume":"115","author":"Wold","year":"2012","journal-title":"Adv. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1073\/pnas.0800200105","article-title":"Hexadecyloxypropyl-cidofovir, cmx001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model","volume":"105","author":"Toth","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3390\/v7031409","article-title":"Valganciclovir inhibits human adenovirus replication and pathology in permissive immunosuppressed female and male syrian hamsters","volume":"7","author":"Toth","year":"2015","journal-title":"Viruses"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.1128\/AAC.03860-14","article-title":"Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed syrian hamsters","volume":"58","author":"Ying","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2014.10.005","article-title":"Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed syrian hamsters, while ribavirin is largely ineffective in this model","volume":"112","author":"Tollefson","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-05-3497","article-title":"Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors","volume":"66","author":"Thomas","year":"2006","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Tollefson, A.E., Ying, B., Spencer, J.F., Sagartz, J.E., Wold, W.S., and Toth, K. (2017). Pathology in permissive syrian hamsters after infection with human adenovirus is the result of virus replication; hadv-c6 replicates more and causes more pathology than hadv-c5. J. Virol.","DOI":"10.1128\/JVI.00284-17"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/cgt.2009.6","article-title":"Ingn 007, an oncolytic adenovirus vector, replicates in syrian hamsters but not mice: Comparison of biodistribution studies","volume":"16","author":"Ying","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/cgt.2009.5","article-title":"An acute toxicology study with ingn 007, an oncolytic adenovirus vector, in mice and permissive syrian hamsters; comparisons with wild-type ad5 and a replication-defective adenovirus vector","volume":"16","author":"Lichtenstein","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.virol.2010.10.041","article-title":"Characterization of species c human adenovirus serotype 6 (ad6)","volume":"412","author":"Weaver","year":"2011","journal-title":"Virology"},{"key":"ref_33","first-page":"223","article-title":"Preparation and titration of cscl-banded adenovirus stocks","volume":"130","author":"Tollefson","year":"2007","journal-title":"Methods Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.virol.2009.08.038","article-title":"Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents","volume":"394","author":"Shashkova","year":"2009","journal-title":"Virology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/jgm.1453","article-title":"Human adenovirus replication in immunocompetent syrian hamsters can be attenuated with chlorpromazine or cidofovir","volume":"12","author":"Diaconu","year":"2010","journal-title":"J. Gene Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin. Pharmacokinets"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/9\/6\/147\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:38:59Z","timestamp":1760207939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/9\/6\/147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,13]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6]]}},"alternative-id":["v9060147"],"URL":"https:\/\/doi.org\/10.3390\/v9060147","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2017,6,13]]}}}